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Abstract
Alzheimer disease (AD) is a heterogeneous and progressive neurodegenerative disease, which in Western so-
ciety mainly accounts for senile dementia. Today many countries have rising aging populations and are facing
an increased prevalence of age-related diseases, such as AD, with increasing health-care costs. Understanding
the pathophysiology process of AD plays a prominent role in new strategies for extending the health of the
elderly population. Considering the future epidemic of AD, prevention and treatment are important goals of
ongoing research. However, a better understanding of AD pathophysiology must be accomplished to make this
objective feasible. In this paper, we review some hot topics concerning AD pathophysiology that have an
important impact on therapeutic perspectives. Hence, we have focused our attention on inflammation, cytokines,
immune response, apolipoprotein E (APOE), cholesterol, oxidative stress, as welll as exploring the related
therapeutic possibilities, i.e., nonsteroidal antiinflammatory drugs, cytokine blocking antibodies, immunother-
apy, diet, and curcumin.
Introduction
The most common form of dementia, Alzheimer dis-ease (AD) is a progressive neurodegenerative illness that
affects nearly 0.6% of those persons aged 65–69, 1.0% of ages
70–74, 2.0% of ages 75–79, 3.3% of ages 80–84, and 8.4% of
persons 85 and older. Thus, it represents a growing public
health problem as life expectancy increases. AD is charac-
terized by progressive memory deficits, cognitive impair-
ment, and personality changes with behavioral and
emotional disturbances that may eventually interfere with
the patient’s ability to perform the basic activities of daily
living. These symptoms are a result of neuronal death, es-
pecially in the limbic and association cortices, which have
roles in memory and navigation.1–3 Neuronal death follows a
period of progressive synaptic dysfunction caused by the
senile plaques, characterized by the accumulation of proteins
in the form of b-pleated sheet fibrils, which are composed
mainly of a 42-amino-acid peptide known as b-amyloid (Ab),
and neurofibrillary tangles, mainly composed by a cyto-
skeletal hyperphosphorylated protein tau. The relative con-
tributions of Ab and tau to the process of neuronal death is
the subject of intense debate in the field. However, the
‘‘amyloid cascade hypothesis’’ supports the idea that Ab is
the main pathogenetic factor of AD due to the aberrant
metabolism of the amyloid precursor protein. The subse-
quent massive production and deposition of the peptide in
extracellular sites are responsible for a concatenate series of
events that result in neurotoxicity and consequent neuronal
death. Many inflammatory mediators have been detected in
several regions of the brain of AD patients and in astrocyte
and microglial cells activation, which have a fundamental
role in the inflammatory pathogenesis, as stated by the am-
yloid cascade=neuroinflammation hypothesis.4–6
Events contributing to AD development are numerous
and complex. The pathogenesis involves a multitude of
variables, many of which remain to be quantified. Recent
work highlighting the importance of immune-inflammatory
responses in AD has led to the prospect of exciting future
therapeutic options. A better understanding of the interplay
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among inflammatory mediators, oxidative stress, and ac-
quired immunity is necessary. Several inflammatory factors
influencing AD development, i.e., environmental factors (pro-
inflammatory phenotype) and=or genetic factors (proin-
flammatory genotype), have been described.4–11
Taking into account the future epidemic of AD, prevention
and treatment are important goals of ongoing research.
Furthermore, a better understanding of AD pathophysiology
must be accomplished to make this objective feasible. In the
present paper, we will review some hot topics concerning
AD pathophysiology and their subsequent relationship to
therapeutic perspectives.
Inflammation and Antiinflammatory Drugs
Inflammation clearly occurs in pathologically vulnerable
regions of the AD brain with the same characteristics of pe-
ripheral inflammatory responses. In the periphery, the
presence of degenerating tissue and the deposition of highly
insoluble abnormal materials are classical stimulants of in-
flammation. Likewise, in the AD brain, the occurrence of
damaged neurons, neuritis, the deposition of highly insolu-
ble Ab42 peptide and neurofibrillary tangles provide obvi-
ous stimuli for inflammation. Moreover, senile plaques in
AD brains are associated with reactive astrocytes and acti-
vated microglial cells, which overexpress cytokines and
acute-phase proteins.4,12,13
The microglial activation can be due to local or systemic
inflammation. In fact, a strong local inflammatory stimulus
such as a previous head trauma is a risk factor for AD, and
several epidemiological studies clearly show that blood ele-
vations of acute-phase proteins, which are markers of sys-
temic inflammatory stimuli, may be risk factors for cognitive
decline and dementia. Furthermore, in experimental animals,
chronic systemic inflammatory response induced by lipo-
polysaccharide administration also induces glial activa-
tion.14–16 A systemic inflammatory challenge in an animal
with a chronic neurodegenerative disease leads to a signifi-
cant increase in acute neurodegeneration, because microglia
in the diseased or aged brain are ‘‘primed’’ and they switch
their phenotype to produce neurotoxic molecules when they
respond to systemic inflammatory signals. It has been sug-
gested that in the diseased or aging brain, signals from sys-
temic inflammation do not evoke a protective homeostatic
response in the host, but evoke an exaggerated response that
contributes to disease progression. In a retrospective general
practitioner database study, the presence of two or more
infections over a 4-year follow-up period was shown to in-
crease the odds of developing AD by around two-fold. Direct
evidence in humans that systemic inflammatory events
might affect AD was shown in a 2-month study of AD pa-
tients, in which systemic infections and raised plasma levels
of interleukin-1b (IL-1b) are both associated with an in-
creased rate of cognitive decline.17,18
Periodontal disease (PD) can be used to establish further
evidence between inflammation and AD. PD is a model of
chronic inflammatory disease able to influence the general
status of health and the respective quality of aging. PDs are a
heterogeneous group of diseases that affect the supporting
structures of the teeth (gingiva, root cement, alveolar bone,
and periodontal ligament). In a generic way, it is possible
distinguish gingivitis as the early stage not involving tooth
attachment and showing an irritation of the gums from the
periodontitis that affects all of the tissues around the tooth
up to the final solution of the unhappy dental loss. The eti-
ology is complex, clinical manifestations differ, and several
classifications have been proposed. The chronic stimulation
of inflammation sustained by Gram-negative anaerobic
bacteria of dental plaque has been correlated with various
systemic diseases, such as preterm and low birth weight,
atherosclerosis and cardiovascular diseases, worsening dia-
betes control, poor wound healing, aspiration pneumonia,
and osteoporosis.19–21
At present, PD is accredited as a complex model, in
which direct and indirect dynamics as well as innate, en-
dogenous, and exogenous factors are involved. In fact, local
acquired immunity reacts, producing inflammatory medi-
ators that are able to alter vessel permeability and allowing
monocytes to penetrate in the inflamed tissue. The chronic
stimulation of inflammation by bacterial plaque involves
several cell populations and several networks of cytokines,
allowing the loss of attachment and the bone defects for-
mation, because they amplify the inflammatory reaction
and activate the effectors mechanism responsible for tissue
destruction. At the same time, bacteria directly or by
means of their lipopolysaccharides could reach the blood
circle.21,22
New links have been hypothesized, on the basis of the
same model, for renal diseases, obesity dismetabolic syn-
drome, and pancreatic cancer; the most interesting link
suggested is that with AD.21 It is important to emphasize
that among periodontal bacteria, some species are capable of
invading the brain, changing the cytokine milieu and possi-
bly contributing to existing pathological mechanisms.23
However, it is likely that the relationship depends on the
systemic inflammation.
This mechanism implies that PD-derived inflammatory
molecules increase brain inflammation. The interaction be-
tween periodontal bacteria and host response results in lo-
cally increased production of inflammatory molecules. The
host response to subgingival periodontal pathogens engages
both innate and instructive immune responses, resulting in
the alteration of local vasculature, generation of an inflam-
matory response, immune cell priming, and the secretion of
inflammatory mediators. In periodontal health, bacteria and
host response are in balance. In gingivitis, the bacterial
challenge elicits an innate immune response in the adjacent
gingival tissue that is able to limit bacterial-induced pathol-
ogy. In periodontitis, the balance between bacteria and host
response is disrupted, resulting in increased inflammatory
infiltrate and the production of inflammatory mediators.
Tissue destruction occurs mainly by activation of osteoclasts,
matrix metalloproteinases, and other proteinases by the host
inflammatory response. In severe PD, these proinflammatory
molecules may induce systemic inflammation and therefore
may access the brain via the systemic circulation. Proin-
flammatory molecules derived locally from periodontal tis-
sue may stimulate trigeminal nerve fibers, leading to
increased brain cytokines. These cytokines may act on the
already primed glial cells, resulting in an amplified reaction
and possible progression of AD. A test of this hypothesis
would entail examining whether PD affects the progression
of AD manifested clinically as earlier onset or as more severe
disease.21,24
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In this context, both cross-sectional and longitudinal
studies have shown that patients with dementia are more
likely to have poor oral health. For example, the Nun Study,
a longitudinal study of aging and AD, has offered an op-
portunity for studying oral health and cognitive function.
Study authors found that a low number of teeth increases the
risk of a higher prevalence and incidence of dementia, even
in patients without the apolipoprotein-E4 (APOE4) allele (see
below), although without conclusive evidence around the
casual role played by each other.21,25–27 In conclusion, evi-
dence-based data regarding the association of PD with
neurodegenerative disorders are still lacking; however, it
seems plausible that via contribution to systemic=brain in-
flammation, brain cytokines increase and activate the neu-
rodegenerative pathway.
The role of local and systemic inflammation raises the
possibility that some proinflammatory cytokine-blocking
antibodies or soluble receptors could also be beneficial for
preventing or treating AD (see below). Moreover, there
are other less potent well-known inflammation-modulating
drugs, such as statins and nonsteroidal antiinflammatory
drugs (NSAIDs) that have few side effects and can be used
with safety, even in very old subjects. On this basis, it is
reasonable to assume that antiinflammatory treatments could
be useful to counteract and to reduce both the age-depen-
dent and the AD-dependent inflammatory status, either
preventing or treating the development of AD. In particular,
several epidemiological studies have suggested that long-
term treatment with NSAIDs may reduce the risk of devel-
oping AD28–31(for statins, see below). On the other hand, a
recent report based on a longitudinal study of men and
women aged 70 years and older with a family history of AD
(ADAPT Study) showed that the use of naproxen or cel-
ecoxib did not improve cognitive function.32 However, sev-
eral critical issues have been raised concerning these study
results; i.e., it has been claimed that the ADAPT Study does
not indicate that NSAIDs, if taken during adulthood and for
an extended period, cannot prevent or delay the onset of
dementia.33 In addition, examining the effects on AD risk of
NSAID use for >5 years in a large health-care database in-
cluding 49,349 cases and 196,850 controls, it has been clearly
demonstrated that long-term NSAID use was protective
against AD. They found that long-term users of NSAIDs
were at lower-than-expected risk of AD. They found that the
protective effect did not seem to be identical for each NSAID:
Some showed clear protective effects, others did not, and in
others the effect on AD risk was unclear. Findings were
clearest for ibuprofen. Ab42-suppressing NSAIDs did not
differ from others, suggesting a key role for cyclooxygenase
inhibition.34
Cytokines and Anticytokines Therapy
As reviewed recently, cytokines are critical in the path-
ophysiology of AD. Although evidence for cellular and
humoral immunity is not present in the AD brains of
individuals, cytokines including tumor necrosis factor-a
(TNF-a and IL-1, as well as other components of the im-
mune response, such as members of the complement
cascade, are present.35,36 Accordingly, cytokine gene poly-
morphisms have been claimed to play a key role in the
pathophysiology of AD. Many genetic studies have re-
ported significant associations between different polymor-
phisms of pro- and antiinflammatory cytokines and AD.
However, there are controversial findings from other
studies that have not replicated the initial results.4 Meta-
analysis provides a means to quantitatively synthesize
association data across studies of the same genetic variant.
The use of the meta-analyses has recently become an
important part of genetic research, mainly to reconcile
previously conducted studies that gave inconsistent results.
Hence, two recent meta-analyses performed by our group
on IL-1b and TNF-a clearly demonstrate the association
between some functional single-nucleotide polymorphisms
(SNPs) and AD.37,38
In this paper, we present data on a meta-analysis focused
on transforming growth factor-b (TGF-b) expressed in the
brain and implicated in the pathophysiology of AD. TGF-b
might have dual proinflammatory and antiinflammatory
roles, although the precise effects of TGF-b in AD are not
well understood. 3,35 However, characterization of the roles
of TGF-b in AD has been addressed in experimental models
of the disease. In transgenic AD-prone mice, overexpression
of TGF-b reduced plaque burden. Activation of TGF-b in
microglial cells might lead therefore to increased degrada-
tion of Ab.39 Polymorphisms in the genes regulating the
expression of TGF-b1 have been hypothesized to enhance
the risk of developing AD. In particular, the most studied
polymorphism of TGF-b, the C=T SNP at the position 509 in
the 50-flanking region of TGF-b1 gene, was shown to be
associated with increased expression and also with in-
creased plasma level of TGF-b.40,41 However, genetic asso-
ciation studies investigating the association with this SNP
and the risk of AD gave very contrasting results. The main
causes explaining the lack of replicability of the results be-
tween different studies seems to be the heterogeneity of the
enrolled study populations and the small sample size of
most studies, leading to a loss of statistical power. To
overcome some of the limitations mentioned above and to
increase the relevance of statistical analysis, a meta-analysis
of all available case–control studies on the association be-
tween TGF-b1 SNPs and the risk of AD has been performed
(Di Bona et al., unpublished observations).
The primary sources of the studies were the AlzGene
database (www.alzgene.org), updated September, 2009,
and the PubMed database. The medical subject headings
were ‘‘TGF-b1,’’ ‘‘polymorphisms,’’ and ‘‘Alzheimer’s dis-
ease’’ for the PubMed search, and the selection of the spe-
cific polymorphism (TGF-b 509; TGF-b 800; TGF-b þ10;
TGF-b þ25) for the search on the AlzGene database. Data
for TGF-b þ25 SNPs were not extensively analyzed by
meta-analysis, because less than four homogeneous sam-
ples were available.42–44 Criteria for the inclusion in the
analysis were: Diagnosis of AD according to the Diag-
nostic and Statistical Manual of Mental Disorders (DSM), and
the National Institute of Neurological Disorders and
Stroke–Alzheimer Diseases and Related Disorders (NINDS-
ADRDA) working group criteria,45 case–control studies,
and available genotype. Analysis was performed as previ-
ously described,37,38,46 and the 95% confidence interval
(95% CI) of the odds ratio (OR) was also calculated. The
putative risk genotype in homozygosity was compared to
the other two aggregated genotypes data, condensing the
results into one statistic.37,38
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TGF-b 509 SNP
Six case–control studies on the association between TGF-b
509 SNP and AD were identified.41,42,47–49 The effect of the
TGF-b 509 TT genotype on the risk of AD is shown in
the Table 1. The effect of the TT genotype seems to increase
the AD risk in two41,48 out of six studies, but a statistically
significant difference was observed only in one.41 The study-
pooled summary OR was 1.00 (TT vs. CTþCC, OR¼ 1.00;
95% CI, 0.78–1.28), suggesting that TT subjects as high TGF-b
producers do not have a higher risk of developing AD. There
was evidence of heterogeneity between the results of indi-
vidual studies (w2¼ 9.42, degrees of freedom [df ]¼ 5,
p¼ 0.09, I2¼ 46.9%).
TGF-b þ10 SNP
Four case–control studies on the association between
TGF-b þ10 SNP and AD were identified.43,44,48,50 The effect
of the TGF-b þ10 CC genotype on the risk of AD is shown
in the Table 1. The effect of the CC genotype seems to in-
crease the AD risk in two out of four studies, but a statis-
tically significant difference was not observed in any
study.43,48 The pooled summary OR was 0.98 (CC vs.
CTþTT, OR¼ 0.98; 95% CI, 0.61–1.57), suggesting that
subjects with the TGF-b þ10 CC genotype do not have a
higher risk of developing AD. Nor did we observe any
difference in disease risk when the TT genotype was com-
pared with the other two aggregated genotypes (CTþCC)
(data not shown).
TGF-b800 SNP
Four case–control studies on the association between TGF-
b 800 SNP and AD were identified.41,42,44,49 The effect of
the TGF-b 800 genotype on the risk of AD is shown in the
Table 1. The effect of the AA genotype was to increase the
AD risk in all the studies, but none of them showed a sta-
tistically significant difference. The pooled summary OR was
1.52 (AA vs. AGþGG, OR¼ 1.52; 95% CI, 0.86–2.96), sug-
gesting that subjects with the TGF-b genotype 800 AA
could have an higher risk of developing AD, although it does
not reach any statistical significance. Nor did we observe a
statistically significant difference in disease risk when the GG
genotype was compared with the other two aggregated ge-
notypes (AAþAG) (data not shown). There was no evidence
of heterogeneity between the results of individual studies
(w2¼ 0.81, df¼ 3, p¼ 0.85, I2¼ 0%).
This study summarizes the evidence to date regarding the
association between common polymorphisms that compre-
hensively capture the variability of the TGF-b gene and the
risk of AD. The analysis of pooled data ruled out the role of
TGF-b SNPs in modifying AD risk that was hypothesized by
some investigators. However, a remarkable heterogeneity
was observed between the results of individual studies,
suggesting differences among the enrolled populations and a
possible population-specific genetic effect of the TGF-b SNPs.
Alternatively, genetic or environmental factors may also play
a contributing role and may explain differences between the
result of individual studies. We could not explain heteroge-
neity by subgroup analysis, taking into account study and
patients characteristics, because of the low number of avail-
able studies.
So these data do not seemingly support a role for TGF-b
SNPs in the pathophysiology of AD. However, inflamma-
tory mediators do not act alone; they act within a complex
network in which they are interacting reciprocally.51 Ac-
cordingly, we found combinations of alleles in eight
inflammatory genes and APOE that distinguish AD risk
groups.52
These studies are relevant to AD treatment. The occur-
rence of a high-risk genetic profile linked to the presence of
high-responder alleles of proinflammatory cytokines or of
low-responder alleles of antiinflammatory cytokines might
suggest the treatment with biologics, such as monoclonal
antibodies directed versus the proinflammatory cytokines.
Decreasing the level of systemic inflammation in AD patients
might be a suitable chemopreventive treatment because
microglia may be activated by systemic stimuli.5,53
In fact, a recently published small, open-label pilot study
suggested that inhibition of the inflammatory cytokine TNF-
a employing the perispinal administration of etanercept
produced sustained clinical improvement in a 6-month,
open-label pilot study in patients with AD ranging from mild
to severe. This approach uses therapeutic delivery of eta-
nercept across the dura via the cerebrospinal venous system,
a confluence of the venous plexuses of the spine and the
brain, in which flow is bidirectional owing to the absence of
venous valves. Continued open-label clinical experience with
this new treatment modality, now for more than 2 years,
suggests that weekly maintenance treatment with perispinal
Table 1. Random-Effects Meta-Analyses Using Genotypic Contrasts for 509, þ10, 800
Transforming Growth Factor-b Single-Nucleotide Polymorphisms
SNP
Studies
(n) Ethnicity
Participants
(n)
Genotypic summary OR
(95% CI), p value
Heterogeneity
p value, I2
509 6 3 Europe (France, The Netherlands, Spain)
2 United States
1 Asia ( Japan)
10,452 TT vs. CTþCC: 1.00
(0.78–1.28), p¼ 0.98
p¼ 0.09; 46.9%
þ10 4 2 Europe (Italy, The Netherlands)
1 United States
1 Asia ( Japan)
7663 CC vs. CTþTT: 0.98
(0.61–1.57), p¼ 0.92
p¼ 0.02; 69.9%
800 4 Europe (Italy, The Netherlands, Spain)
1 United States
9898 AA vs. AGþGG: 1.52
(0.86–1.20), p¼ 0.15
p¼ 0.85; 0%
Di Bona et al., unpublished observations.
SNP, Single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval.
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etanercept may have a sustained positive effect. In addition,
rapid clinical improvement within minutes of dosing has
been observed on a repeated basis in multiple patients. It is
hypothesized that perispinal administration of etanercept
may enable rapid delivery to the central nervous system
(CNS) via the cerebrospinal venous system, resulting in im-
provement in synaptic mechanisms that have been dysre-
gulated by excess TNF-a. Although some benefit was
observed, firm conclusions cannot be drawn at present from
these small trials. Perispinal etanercept for AD merits further
study in randomized clinical trials.54–56
Immune Response and Immunotherapy
Some evidence suggests the involvement of a systemic
immune response in AD, although so far it is poorly char-
acterized. However, changes in the distribution and reac-
tivity of immune cells in the blood have been observed.
Neuroinflammation induces the efflux of CNS proteins, such
as Ab, or inflammatory mediators across the blood–brain
barrier. This may cause systemic immune reaction and re-
cruitment of myeloid or lymphocytic cells into the CNS.
Thus, communication between the CNS and immune system
in AD could influence both the lymphocyte distribution in
the blood and the production of immune mediators.11 Ac-
tually peripheral blood mononuclear cells (PBMCs) from AD
patients produce higher levels of some cytokines, such as IL-
1b and IL-6, compared to levels of PBMCs from control
subjects.57 Moreover, an immune disregulation was recently
documented as dramatic alterations on CD4þ subsets in
patients with mild AD. In particular, decreased percentages
of naı¨ve cells and an increase of memory cells, an increased
number of CD4þ lymphocytes that lack the co-stimulatory
molecule CD28, and a reduction of CD4þCD25high T regu-
latory cells have been observed.58
To investigate the systemic signs of immune processes in
AD, Pellicano` et al. (unpublished observations) have exam-
ined the distribution of lymphocyte blood subsets in AD
patients, comparing the results to data obtained in healthy
controls. A decrease of B lymphocytes in AD patients due to
a decrease of exhausted memory cells has been observed. In
addition, the expression of activation markers on PBMCs
from AD patients activated in vitro by recombinant (r)Ab42,
was increased respect to controls. Stimulation by rAb42 also
induced the production of the proinflammatory and anti-
inflammatory cytokines, chemokines, and growth factors
(Table 2). This kind of study, which supportsthe involvement
of systemic immunity in AD patients, can provide the basis
for the search of immune biomarkers in AD for monitoring
the effectiveness of therapeutic interventions.10
In fact, immune-based therapies targeting Ab have gen-
erated considerable interest as a possible mechanism for re-
ducing Ab in the brain. Current views see immunization
with the Ab peptide or the infusion of preformed antibody
specific for human Ab as possible therapeutic approaches to
improve the cognitive status in AD patients. Animal models
of AD have provided positive results from both approaches.
Thus, an initial clinical trial using immunization with human
Ab in AD patients was started, but then was halted because
of a high incidence of meningoencephalitis. Passive immu-
notherapy in animal models of AD has provided similar
benefits comparable to those seen with active immunother-
apy, and in human beings it has the potential of being ef-
fective without inducing T cell–mediated encephalitis.59,60
Thus, intravenous immunoglobulin (IVIg) has been pro-
posed as a potential agent for AD immunotherapy because it
contains antibodies against Ab. In a recent study, adminis-
tration of IVIg to patients with mild AD led to transient,
reproducible, and dose-dependent increases in serum anti-
Ab antibody titers and parallel increases in plasma Ab levels.
After 6 months of IVIg therapy, the cerebrospinal fluid (CSF)
Ab levels decreased, whereas after 3 months without IVIg, a
washout period, CSF Ab levels increased to their pretreat-
ment baseline levels. When IVIg therapy was restarted, a
decrease in CSF Ab levels was again observed. In the
meantime, a mean improvement of 2.5 points in Mini-Mental
State Examination (MMSE) scores after 6 months was ob-
served, with a decline of these scores toward baseline during
the washout period.61
Furthermore, a retrospective case–control analysis dem-
onstrated that previous treatment with IVIg is associated
with a reduced risk of developing AD. Compared with un-
treated controls, patients who received previous IVIg for
other indications had a 42% lower risk of developing AD
over a period of approximately 4 years. This study provides
epidemiologic evidence that previous IVIg may have a pro-
tective effect on the development of AD.62 It is well known
that IVIg contains natural anti-Ab antibodies, and these
natural antibodies have the capacity to prevent Ab oligomer-
induced neurotoxicity in N2A neuroblastoma cells. This
neuroprotective effect may reflect the therapeutic potential of
the natural anti-Ab antibodies found in IVIg for the treat-
ment of patients with AD.63 It is also possible that other
activities of IVIg, unrelated to its content of anti-Ab anti-
bodies, such as the modulation of inflammatory and immune
reactions, may complement the effects of anti-Ab antibodies
on cognitive function in AD patients. The mechanisms
of action of IVIg are complex, involving modulation of
expression and function of Fc receptors, interference with
Table 2. Cytokines, Chemokines, and Growth Factors
Whose Secretion by Alzheimer Disease Peripheral
Blood Mononuclear Cells Is Significantly
Increased When Stimulated with rAb42
with Respect to Control Cultures
Cytokines Chemokines Growth factors
IL-1b Eotaxin GM-CSF
IL-1ra MIP-1b G-CSF
IL-6 RANTES
IFN-g
TNF-a
IL-10
IL-8
Cells were cultured in 24-well flat-bottomed plates at 1.5106 cells
per well in RPMI medium. The PBMCs were either unstimulated or
stimulated by oligomeric rAb42 (10mg=mL). The supernatants of the
cultured PBMCs were collected and the following cytokines and
chemokines were evaluated using Luminex 100 (BioRad) according
to manufacturer’s instructions (Pellicano` et al., unpublished obser-
vations).
IL-1, Interleukin-1; IFN-g, interferon-g; TNF-a, tumor necrosis
factor-a; MIP-1b, macrophage inflammatory protein-1b; GM-CSF,
granulocyte-macrophage colony-stimulating factor; G-CSF, granulo-
cyte colony-stimulating factor.
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activation of complement and the cytokine network and of
idiotype network, regulation of cell growth, and effects on
the activation, differentiation, and effector functions of den-
dritic cells and T and B cells.64 These promising preliminary
findings encourage additional research involving both ade-
quate, well-controlled, randomized clinical trials to evaluate
the effects of IVIg more thoroughly in AD and well-designed
studies that gain insight to immune response in AD patients.
APOE, Cholesterol, and Diet
The APOE4 allele is the only known genetic variant that
has been clearly associated with increased risk of late-onset
AD. In the human population, three variants of the APOE
gene have been found—e2, e3, and e4—that are able to in-
fluence the concentration of the lipoprotein in the blood-
stream. The APOE proteins are associated with 10% of the
difference in cholesterol concentration in the bloodstream
whereas the allele e4 is tightly associated with the highest
concentration. It has been demonstrated that subjects carry-
ing APOE4 allele have a nearly double chance of developing
AD whereas individuals not carrying the APOE4 allele have
a decreased risk of AD by 40%. Yet fewer than half of all AD
patients possess the e4 allele and not all e4 carriers develop
the disease. It has also been suggested that the main effect of
the allele is to anticipate the onset of the disease.4,65,66
Although there have been numerous studies attempting to
elucidate the underlying mechanism accounting for in-
creased risk, the influence of APOE4 on AD onset and pro-
gression needs more convincing and critical evidence.
However, prevailing indications suggest that the differential
effects of APOE isoforms on Ab aggregation and clearance
play the major role in AD pathogenesis. Actually, the e4
allele accelerates amyloid deposition and promotes Ab ag-
gregation in cholesterol-rich lipid rafts, enhancing aggrega-
tion into senile plaques. In addition to its role in Ab
aggregation, it has been well argued that APOE4 promotes
inflammatory responses. Other potential mechanisms, such
as the differential modulation of neurotoxicity and tau
phosphorylation by APOE4 isoforms, as well as its role in
synaptic plasticity, have not been ruled out.4,67–69
On the other hand, the association between APOE, cho-
lesterol, and AD has been the subject of intense scrutiny by
numerous groups. High cholesterol levels at midlife are a
considerable risk factor for dementia=AD in most of long-
term follow-up studies. Moreover, the power of dietary fats
on AD development was observed in APOE4 subjects only.
To get a glimpse of cholesterol expression on AD, we have to
consider that the brain is very rich in cholesterol that is ac-
tively turned over among neurons and glial cells via apoli-
poproteins and their receptors play an essential role in
synaptic plasticity. In addition, different cholesterol synaptic
distribution depends on different APOE alleles. The best-
studied role of cholesterol in AD is in amyloid precursor
protein (APP) processing and Ab generation. Increased
cholesterol leads to increased cleavage of APP and increased
Ab production, whereas reduction of cellular cholesterol
decreases the g-secretase activity, which is responsible for Ab
generation.4,70,71
Epidemiological studies have suggested a possible pro-
tective effect for the cholesterol-lowering statin drugs that
inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase,
the enzyme that catalyzes the rate-limiting step in choles-
terol, in AD patients. Numerous studies have examined the
role of statins in the prevention of dementia and treatment of
established AD. As matter of fact, as a biological point of
view, it seems feasible that statins could prevent dementia
due to their role in cholesterol reduction and in antiin-
flammatory activities that are not directly dependent on
lowering blood cholesterol. However, while evidence from
retrospective case–control studies suggests a beneficial role
of statins in the prevention of AD, a similar benefit has not
been established in prospective cohort studies or random-
ized clinical trials.4,72,73
On the other hand, cognitive impairment can be influenced
by a number of other factors. The potential effect of nutrition
has become a topic of increasing scientific and public interest.
In particular, there are arguments that nutrients (food and=or
supplements), such as vitamins, trace minerals, and lipids,
can affect the risk of cognitive decline and dementia, espe-
cially in frail elderly people at risk of deficiencies. Un-
mistakably, aging is associated with cognitive dementia and
AD; concomitantly, aging is also associated with malnutrition
and reduced intake of micro- and macronutrients.74 The role
of diet in cognitive decline has not been looked into broadly,
but because several dietary factors affect the risk of cardio-
vascular disease and some studies have suggested a link
between cognitive decline and cardiovascular disease,75 dia-
betes mellitus,76 and hypertension,77 it might be assumed that
dietary intake might also influence the risk of dementia.
High energy intake and increase in body mass index dur-
ing middle age have been associated with defeat of cognitive
function in old age,78 whereas low calorie intake was pro-
tective against AD.79 Nonetheless, the diet of AD patients
seems to have deficiencies in omega-3 fatty acids, especially
docosahexaenoic acid=eicosapentaenoic acid long-chain
omega-3 fatty acids, and too few antioxidants. Unfortunately,
there are only a few studies comparing diets of AD patients
with age-matched controls, and they tend to show AD pa-
tients with lower amounts of omega-3 fatty acids, excess
omega-6 fatty acids (which would also cause inflammation),
too much sugar (insulin resistance and metabolic syndrome),
and fewer antioxidants.80 Unfortunately, in the Rotterdam
study, no correspondence was found between increased risk
of dementia and dietary intake rich in saturated fatty acids,
trans fatty acids, and cholesterol.81
On the other hand, there are studies showing a positive
association between high intake of saturated and trans-
unsaturated (hydrogenated) fats and increased risk of AD,
because intake of polyunsaturated and monounsaturated
fats seems to be protective against cognitive decline in the
elderly.82,83 Overall the role of lipid in AD is difficult to
pinpoint because the presence of the APOE4 allele seems to
respond more efficiently to diet modulation, whereas the
presence of APOE3 and APOE2 is less influenced by diet.84,85
Also homocysteine-related vitamins and antioxidant nu-
trients (vitamins E and C, carotenoids, flavonoids, enzymatic
cofactors) seem to have a role in AD risk, and epidemiologic
data suggest a protective role of the B vitamins, especially
vitamins B9 and B12, regarding cognitive decline and de-
mentia.86 Nonetheless other studies have shown conflicting
results.87
Ambiguous results are evident also on the dietary fruit
and vegetables supplementation. The Chicago Health and
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Aging Project has shown an association between cognitive
decline with older age and high vegetable but not fruit
consumption,88 whereas intervention studies on rats given a
dietary supplement of fruit and vegetables extracts have
shown a slowed age-related decline in neuronal and cogni-
tive functions.89 However, the results on antioxidant nutri-
ents may suggest the importance of having a balanced
combination of several antioxidant nutrients to exert a sig-
nificant effect on the prevention of cognitive decline and
dementia, while taking into account the potential adverse
effects of these nutrients.84
Higher adherence to a Mediterranean diet seems to be
associated with borderline reduction in risk for developing
mild cognitive impairment (MCI) and a reduction risk for
conversion from MCI to AD,26 whereas a Japanese diet
seems to be less protective.90 The substantial difference
consists in the intake of animal fat and complex carbohy-
drates, whereas a Japanese diet is poor in animal fat and rich
in complex carbohydrates.
Overall, these studies take in account several among the
known confounding factors and consider the impact of food
habits, such as the regional cultures, social status, and edu-
cational level, together with the genetic effect. In conclusion,
there are a great amount of large prospective studies dem-
onstrating association with lower all-cause and cause-specific
mortality; nevertheless, there is a need of further analysis to
verify if those association can be a useful tools for preventing
diseases.
Oxidative Stress and Therapeutic Perspectives
Oxidative stress is considered one of the most critical
among the factors linked to AD pathophysiology.91 Actually,
besides the pathological hallmarks of the disease, AD brains
exhibit evidence of reactive oxygen species (ROS)–mediated
injury, and free radical oxidative damage to key intracellular
targets such as DNA or proteins has been shown to be a
major cause of the neuronal cell death related to AD.92
Oxidative stress is the result of an unbalance between oxi-
dant production and antioxidant defenses. The brain, com-
pared to other organs, is more susceptible to oxidative stress
for the following reasons: (1) High content of peroxidizable
unsaturated fatty acids; (2) high oxygen consumption per
unit weight; (3) high content of lipid peroxidation key in-
gredients (iron and ascorbate); and (4) the scarcity of anti-
oxidant defenses systems. Under normal conditions, free
radicals are produced from a number of sources, among
which are enzymatic, mitochondrial, and redox metal
ion–derived sources as well as inflammatory response.93 In
AD, an overproduction of free radicals seems to be mostly
related to mitochondrial dysfunctions, to the Ab peptides
themselves, and to the presence of unbound trace metal ions.
Today, it is evident that the three sources are not indepen-
dent from each other, and recent hypotheses predict that, in
the early stages of the disease, Ab peptide enters the mito-
chondria where it induces ROS generation and subsequent
oxidative stress.94
The mechanisms associated with Ab-mediated neurotox-
icity are still partially unknown, but there is evidence sug-
gesting that oxidative stress plays a key role.94,95 Several
groups showed that among the 42 amino acids forming
Ab(1–42), the methionine located at position 35 is critical for
Ab-associated ROS production and neurotoxicity.96,97 Fur-
thermore, activation of microglial nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase by Ab oligomers,
Ab fibrils, and senile plaque is responsible for the production
of both extracellular and intracellular ROS, with direct tox-
icity to neurons and sustained production of several proin-
flammatory and neurotoxic cytokines.98,99
On the other hand, irrespective of the source and mecha-
nisms that lead to the generation of intracellular toxic
oxidants, mammalian cells have developed highly refined
inducible systems to counteract stressful conditions and to
fight off oxidation.100 Activation of antioxidant pathways is
particularly important for tissue with relatively weak anti-
oxidant defenses, such as the brain. Increasing evidence
points out that reduced cellular expression and activity of
antioxidant proteins are fundamental triggers for AD.101
Aging, the major risk factor for AD, leads to loss of the free
radical scavenging ability by endogenous mechanisms.102
Cortical and hippocampal oxidative stress is a very early
event in the pathophysiology of sporadic AD and correlates
with the development of specific cognitive deficits. This re-
gional distribution has been strictly related to the amyloid
load, because the cerebellum showed low levels of Ab, no
oxidative stress relative to controls, and essentially no neu-
ronal loss.103,104
Among cellular antioxidant defenses, heat shock proteins
have been regarded as cytoprotectants protecting the brain
cells from oxidative damages encountered during the neu-
rodegenerative diseases progression. Heme oxygenase-1
(HO-1) is a 32-kD stress protein that catalyzes the degrada-
tion of heme to biliverdin.105 The HO-1 gene is redox regu-
lated, and its activation represents a protective system
potentially active against brain oxidative injury.106 Its ex-
pression in AD patients brain is significantly increased,107
and the spatial distribution of HO-1 expression in diseased
brain is essentially identical to that of pathological expres-
sion of tau.108 HO-1 immunoreactivity is greatly increased in
neurons and astrocytes of the hippocampus and cerebral
cortex of individuals with AD and colocalizes in senile pla-
ques and neurofibrillary tangles. HO-1 is thought to down-
regulate the production of tau protein, and recently HO-1
polymorphisms have been considered as a possible respon-
sible for increased AD susceptibility.109 Deregulation of the
HO system has been associated with the pathogenesis of
AD110, multiple sclerosis,111 and brain aging.112 Many stud-
ies clearly demonstrate that activation of HO-1 in neurons is
strongly protective against oxidative damage and cell
death.113,114 In fact, the activation of HO-1 seems to represent
an important defensive mechanism for neurons exposed to
oxidative stress. Thus, modulation of HO-1 should represent
a potential pharmaceutical strategy for the treatment of
neurodegenerative disorders.8
Because oxidative stress may be responsible for some as-
pects of AD neurodegeneration, and because to date most of
the available treatments are merely symptomatic, extensive
research has been aimed at reducing the effects of oxidative
stress to prevent AD progression by using free radical
scavengers. Thus, one therapeutic strategy is to delay AD
onset long enough so as to slow the neuronal damage as-
sociated with Ab-induced oxidative stress, particularly Ab-
induced lipid peroxidation. Brain-accessible antioxidants
potentially may provide the means of implementing this
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therapeutic strategy of delaying the onset of AD, acting as
neuroprotective agents. Spices and herbs often contain active
phenolic substances endowed with potent antioxidative and
chemopreventive properties,115 and recently a series of pa-
pers have focused on specific neuroprotective effects of some
of those polyphenols derived from nutritional sources.116
Curcumin (1,7-bis[4-hydroxy-3-methoxyphenyl]-1,6-hepta-
diene-3,5-dione), a coloring agent and food additive com-
monly used in Indian culinary and traditional medical
preparations from time immemorial, is extracted from the
rhizome of Curcuma longa.117 It is a polyphenolic substance
that has the potential to inhibit lipid peroxidation and to ef-
fectively intercept and neutralize ROS (superoxide, peroxyl,
hydroxyl radicals)118,119 and nitric oxide (NO)-based free
radicals (nitric oxide and peroxynitrite).120 It is generally
assumed that the phenol moiety is responsible for anti-
oxidant properties of any plant phenolic compound. Con-
sequently, the free radical chemistry of curcumin (an
o-methoxyphenol derivative) has focused on its phenol ring.
The possible involvement of the b-diketone moiety in the
antioxidant action of curcumin has been considered,121 and
the H-atom donation from the b-diketone moiety to a lipid
alkyl or a lipid peroxyl radical has been reported as the
potentially more important mechanism underlying its anti-
oxidant action.122 Of particular interest is the ability of cur-
cumin to inhibit cyclooxygenase enzymes123 and to reduce
the activation of nuclear transcription factor NF-kB.124 Its
antiinflammatory properties and cancer-preventive activities
have been consistently reported using in vitro and in vivo
models of tumor initiation and promotion.125
In addition to its ability to scavenge carcinogenic free
radicals,126 curcumin also interferes with cell growth through
inhibition of protein kinases. Although the exact mechanisms
by which curcumin promotes these effects remains to be
elucidated, the electrophilic properties of this yellow pig-
ment appear to be an essential component underlying its
pleiotropic biological activities. Curcumin contains two
electrophilic a,b-unsaturated carbonyl groups, which can
react with nucleophiles such as glutathione.127 In addition,
curcumin can increase the activity of g-glutamyl-cysteinyl
synthetase and other glutathione (GSH)-linked detoxifying
enzymes.128 Low concentrations of curcumin potently induce
HO-1 expression and activity in vascular endothelial cells, in
rat astrocytes, and in cultured hippocampal neurons. Pre-
incubation (12 h) of cultured neurons with a low concentra-
tion of curcumin resulted in an enhanced cellular resistance
to glucose oxidase–mediated oxidative damage. This cyto-
protective effect was considerably attenuated by zinc pro-
toporphyrin IX, a specific inhibitor of HO activity.129–131 In
other experiments, it has been demonstrated the efficacy of
curcumin to protect cortical neurons against apoptotic cell
death induced by Ab.132 The ability of curcumin to induce
HO-1 can explain, at least in part, the strong antioxidant and
antiinflammatory properties of curcumin, which depend
more by its action as cellular signals than by its radical
scavenger effect.133
The involvement of curcumin in restoring cellular ho-
meostasis and rebalancing redox equilibrium by the activa-
tion of defensive genes suggests that it might also be a useful
adjunct in AD treatment. Neuroprotective effects of curcu-
min have been demonstrated by Rajakrishnan134 in ethanol-
induced brain damage; oral administration of curcumin in
rats caused a significant reversal in lipid peroxidation, brain
lipid modifications, as well as increase in glutathione levels.
Epidemiological studies have suggested that curcumin, as
one of the most prevalent nutritional and medicinal com-
pounds used by the Indian population, is responsible for the
significantly reduced (4.4-fold) prevalence of AD in India
compared to United States.135 Furthermore, elderly Singa-
poreans who ate curry with turmeric had higher MMSE
scores than those who did not.136 However, the relatively
short duration of follow up, cultural factors, and other po-
tential confounders suggest caution in interpreting these
findings. Consistent with these data, convincing evidence
has been provided that dietary curcumin given to an AD
transgenic mouse model (Tg2576) for 6 months resulted in a
suppression of indices of inflammation and oxidative dam-
age in the brain of these mice and reversed Ab-induced
cognitive deficits.137,138 The same group demonstrated in a
successive study that curcumin was a better Ab40 aggrega-
tion inhibitor than ibuprofen and naproxen and prevented
Ab42 oligomer formation and toxicity at very low concen-
trations (between 0.1 and 1.0 mM).139 They also showed that
curcumin readily entered the brain to label plaques in vivo,
inhibiting the formation of Ab oligomers and their toxicity.
Among the several mechanisms by which curcumin is able to
clear amyloid is the induction of heat shock proteins (HSPs),
which function as molecular chaperones to block protein
aggregate formation.140
Recently, curcumin has been evaluated, with preliminary
encouraging results, in a pilot clinical trial in AD patients.141
Curcumin is highly lipophilic and might cross the blood–
brain barrier and reach the brain, and, although its bioavail-
ability is very low, because the drug is rapidly metabolized by
conjugation, curcumin may reach brain concentrations suffi-
cient to activate signal transduction events and to decrease Ab
aggregation.142 Other plant-derived phenolic agents with
analogous chemical structures to curcumin have been dem-
onstrated to strongly activate HO-1 expression and to defend
cells against oxidative stress—in particular carnosol,143 zer-
umbone,144 resveratrol,145 rosolic acid,146 and sulfora-
phanes.147 Furthermore it has been demonstrated that other
phenolics, such as caffeic acid phenethyl ester (CAPE),130
ethyl ferulate (EFE),148 and epigallocatechin-3-gallate
(EGCG),149 are able to protect neurons via HO-1 induction.
Conclusions
Today, many countries have rising aging populations and
are facing an increased prevalence of age-related diseases,
such as AD, with growing health-care costs. Understanding
the AD pathophysiology process plays a prominent role in
developing new strategies that can extend the health of the
elderly population. In fact, taking into account the future
epidemic of AD, prevention and treatment are important
goals of ongoing research. As discussed in this review,
events contributing to the onset and development of AD
are numerous and complex. We have focused our attention
on many hot topics involved in AD pathophysiology,
such as inflammation, cytokines, immune response, APOE,
cholesterol, and oxidative stress, and have explored the re-
lated therapeutic possibilities, i.e., NSAIDs, cytokine block-
ade, immunotherapy, diet, and curcumin. We believe that
the investigation of AD pathophysiology, particularly
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disentangling inflammation, is likely to provide important
clues about how to develop drugs that can slow or delay AD.
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